

Literatur

1. WHO. The World Health Organization Coronavirus Disease (COVID-19) Dashboard. 02.11.2020; <https://covid19.who.int/>.
2. Hoffmann, M., H. Kleine-Weber, S. Schroeder, N. Kruger, T. Herrler, S. Erichsen, et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*, 2020. 181(2): 271-280 e8.
3. Zhou, F., T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*, 2020. 395(10229): 1054-1062.
4. Guzik, T.J., S.A. Mohiddin, A. Dimarco, V. Patel, K. Savvatis, F.M. Marelli-Berg, et al., COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. *Cardiovascular research*, 2020. 116(10): 1666-1687.
5. Ellinghaus, D., F. Degenhardt, L. Bujanda, M. Buti, A. Albillos, P. Invernizzi, et al., Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *The New England journal of medicine*, 2020.
6. Group, R.C., P. Horby, W.S. Lim, J.R. Emberson, M. Mafham, J.L. Bell, et al., Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *The New England journal of medicine*, 2020.
7. Böhm, M., N. Frey, E. Giannitsis, K. Sliwa, and A.M. Zeiher, Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation. *Clinical Research in Cardiology*, 2020.
8. Huang, C., Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*, 2020. 395(10223): 497-506.
9. Puntmann, V.O., M.L. Carerj, I. Wieters, M. Fahim, C. Arendt, J. Hoffmann, et al., Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*, 2020.
10. Guo, T., Y. Fan, M. Chen, X. Wu, L. Zhang, T. He, et al., Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*, 2020.
11. Tavazzi, G., C. Pellegrini, M. Maurelli, M. Belliati, F. Scuti, A. Bottazzi, et al., Myocardial localization of coronavirus in COVID-19 cardiogenic shock. *Eur J Heart Fail*, 2020. 22(5): 911-915.
12. Lindner, D., A. Fitzek, H. Brauninger, G. Aleshcheva, C. Edler, K. Meissner, et al., Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. *JAMA Cardiol*, 2020.
13. Kim, J.C., J.Y. Kim, H.A. Kim, and S. Han, COVID-19-related myocarditis in a 21-year-old female patient. *European heart journal*, 2020. 41(19): 1859.
14. Hu, H., F. Ma, X. Wei, and Y. Fang, Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. *European heart journal*, 2020.
15. Caforio, A.L., S. Pankuweit, E. Arbustini, C. Basso, J. Gimeno-Blanes, S.B. Felix, et al., Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *European heart journal*, 2013. 34(33): 2636-48, 2648a-2648d.
16. Wang, Y., Z. Wang, G. Tse, L. Zhang, E.Y. Wan, Y. Guo, et al., Cardiac arrhythmias in patients with COVID-19. *J Arrhythm*, 2020. 36(5): 827-836.
17. Hansson, G.K., Inflammation, atherosclerosis, and coronary artery disease. *The New England journal of medicine*, 2005. 352(16): 1685-95.
18. Kwong, J.C., K.L. Schwartz, M.A. Campitelli, H. Chung, N.S. Crowcroft, T. Karnachow, et al., Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. *The New England journal of medicine*, 2018. 378(4): 345-353.
19. Thygesen, K., J.S. Alpert, A.S. Jaffe, B.R. Chaitman, J.J. Bax, D.A. Morrow, et al., Fourth Universal Definition of Myocardial Infarction (2018). *Circulation*, 2018. 138(20): e618-e651.
20. Piccolo, R., D. Bruzzese, C. Mauro, A. Aloia, C. Baldi, M. Boccanatelli, et al., Population Trends in Rates of Percutaneous Coronary Revascularization for Acute Coronary Syndromes Associated With the COVID-19 Outbreak. *Circulation*, 2020. 141(24): 2035-2037.
21. Kessler, T., T. Graf, I. Hilgendorf, K. Rizas, E. Martens, C. von Zur Muhlen, et al., Hospital admissions with acute coronary syndromes during the COVID-19 pandemic in German cardiac care units. *Cardiovascular research*, 2020. 116(11): 1800-1801.
22. Levi, M., J. Thachil, T. Iba, and J.H. Levy, Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematol*, 2020. 7(6): e438-e440.
23. Fauvel, C., O. Weizman, A. Trimaille, D. Mika, T. Pommier, N. Pace, et al., Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. *European heart journal*, 2020.
24. Middeldorp, S., M. Coppens, T.F. van Haaps, M. Foppen, A.P. Vlaar, M.C.A. Muller, et al., Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost*, 2020. 18(8): 1995-2002.
25. Nicolaj, L., A. Leunig, S. Brambs, R. Kaiser, T. Weinberger, M. Weigand, et al., Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy. *Circulation*, 2020. 142(12): 1176-1189.
26. Paranjpe, I., V. Fuster, A. Lala, A.J. Russak, B.S. Glicksberg, M.A. Levin, et al., Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. *Journal of the American College of Cardiology*, 2020. 76(1): 122-124.
27. Nadkarni, G.N., A. Lala, E. Bagiella, H.L. Chang, P. Moreno, E. Pujadas, et al., Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study. *Journal of the American College of Cardiology*, 2020.
28. Ferrario, C.M., J. Jessup, M.C. Chappell, D.B. Averill, K.B. Brosnihan, E.A. Tallant, et al., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation*, 2005. 111(20): 2605-10.
29. Cheng, X., Y.M. Liu, H. Li, X. Zhang, F. Lei, J.J. Qin, et al., Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. *Cell Metab*, 2020.
30. Zhang, X.J., J.J. Qin, X. Cheng, L. Shen, Y.C. Zhao, Y. Yuan, et al., In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. *Cell Metab*, 2020. 32(2): 176-187 e4.
31. Kessler, T. and H. Schunkert, Inhibitors of the renin-angiotensin system and SARS-CoV-2 infection. *Herz*, 2020. 45(4): 323-324.
32. Di Castelnuovo, A., S. Costanzo, A. Antinori, N. Berselli, L. Blandi, M. Bonaccio, et al., RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. *Vascul Pharmacol*, 2020: 106805.
33. Mancia, G., F. Rea, M. Ludergmani, G. Apolone, and G. Corrao, Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. *The New England journal of medicine*, 2020. 382(25): 2431-2440.
34. Pinto-Sietsma, S.J., M. Flossdorf, V.R. Buchholz, J. Offerhaus, H. Bleijendaal, M. Beudel, et al., Antihypertensive drugs in COVID-19 infection. *Eur Heart J Cardiovasc Pharmacother*, 2020.
35. Cannata, F., M. Chiarito, B. Reimers, E. Azzolini, G. Ferrante, I. My, et al., Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. *Eur Heart J Cardiovasc Pharmacother*, 2020.
36. Beigel, J.H., K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, A.C. Kalil, et al., Remdesivir for the Treatment of Covid-19 - Final Report. *The New England journal of medicine*, 2020.